Eli Lilly ($LLY) reached the FDA finish line with its cancer treatment Cyramza (ramucirumab), its star oncology candidate. The Indianapolis-based company nabbed an approval in gastric cancer, for patients whose tumors can't be removed or those whose cancer has spread after previous treatment. Peak sales? As high as $1.3 billion, analysts say. Release | Report